The Microbiome and Cancer Treatment

Overcoming Resistance and Enhancing Efficacy
Erscheinungsjahr 2026
ISBN: 978-0-443-33206-7
Verlag: Elsevier Science

Buch, Englisch, 380 Seiten, Format (B × H): 191 mm x 235 mm, Gewicht: 450 g

The Microbiome and Cancer Treatment: Overcoming Resistance and Enhancing Efficacy delves into the intricate relationship between the microbiome and cancer treatment, highlighting the microbiome's critical role in drug resistance and therapeutic efficacy. The book's chapters are meticulously organized to provide a deep understanding of how the microbiome interacts with the immune system and influences cancer development and response to therapies. This book opens new avenues for investigation by providing a better understanding of the mechanisms of resistance and the role of microbiome alterations in chemoresistance.

Sections also address the complex "chicken-or-egg" relationship between microbiome alterations and chemoresistance. A diverse blend of chapters foster interdisciplinary collaboration across fields such as immunology, microbiology, oncology, and pharmacology, promoting holistic approaches to cancer treatment. Readers will benefit by gaining awareness and a better understanding of how the microbiome impacts health, particularly in the context of cancer, leading to more informed health choices.

Autoren/Hrsg.

Aggarwal, Sadhna

Singh, Arun Kumar

Dhanawat, Meenakshi

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie

Inhaltsverzeichnis

1. Understanding the Microbiome: Microbiome and Immune System Interactions
2. The Microbiome: Its Impact on Cancer Development and Therapeutic Responses
3. Microbiome Dynamics in Cancer Treatment: Impact of Chemotherapy on the Microbiome
4. Microbiome as a Modulator of Immunotherapy: Synergistic Effects of the Microbiome in Immunotherapy
5. Microbiome-Based Strategies to Overcome Chemoresistance: Probiotics and Prebiotics in Cancer Therapy
6. Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
7. The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy
8. Cancer pharmacomicrobiomics: targeting microbiota to optimize cancer therapy outcomes
9. Gut microbiome in modulating immune checkpoint inhibitors
10. Microbiome-based diagnostics and biomarkers: The search for mechanistic connections
11. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors
12. Current challenges and Future Prospects for Microbiome Research in Cancer Treatment

Über Autor(innen)

Singh, Arun Kumar
Arun Kumar Singh is an Assistant Professor in the Department of Pharmacy at University School of Pharmaceutical Sciences, Rayat Bahra University V.P.O. Sahauran, India. He completed his M.Pharm in Pharmaceutics from Galgotias University, Greater Noida. His research interests include nano-formulation, blockchain, IoT, machine learning, artificial intelligence, big data analytics, cancer biology, and neuroscience. He has contributed to academic books and book chapters and has published review articles in the areas of pharmaceutical sciences and healthcare technology. His work focuses on interdisciplinary approaches integrating pharmaceutical research with emerging digital and computational technologies.

Aggarwal, Sadhna
Dr. Aggarwal is currently a senior postdoctoral fellow at the MD Anderson Cancer Center, Texas, USA. She completed Ph.D. from AIIMS, New Delhi under supervision of Prof. S. N. Das. During PhD, wherein she successfully addressed various aspects of local immunopathology in oral squamous cell carcinoma (OSCC). She published dozens of articles and several book chapters. She is an editorial board member of several indexed reputed international journals.

Dhanawat, Meenakshi
Dr. Meenakshi Dhanawat is an Associate Professor at the Amity Institute of Pharmacy, Amity University Haryana, with over 18 years of experience in Pharmaceutical Sciences and Medicinal Chemistry. She completed her Master's degree at NIPER, Mohali, focusing on glycosylamino acids, and earned her Ph.D. from IIT-BHU, Varanasi, investigating CNS drug delivery targeting 5HT1A/2A receptors. Her research encompasses synthetic and heterocyclic chemistry, nanotechnology, drug delivery systems, prodrug design, complexation, polymer chemistry, and herbal drug extraction. Dr. Dhanawat has received notable international recognition, including a travel grant from the AAPS Drug Delivery and Development section for the 2010 National Biotechnology Conference in California, and international travel grants from DBT and DST, Government of India, for conferences in California and Munich. Her distinguished honors include the Rajiv Gandhi National Fellowship, affirming her sustained contributions to pharmaceutical research and academic excellence.